The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
May 17th 2024
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
US Biosimilars Substantially More Expensive Than Those in Germany, Switzerland
December 5th 2022Due to anticompetitive practices, the United States lags Germany and Switzerland in the number of biosimilars on the market, while also having substantially higher prices for both biosimilars and reference products.
Read More
Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts
November 26th 2022Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Read More
Dr Timothy Murphy: Strong Communication Is Necessary for Practices Stocking Multiple Biosimilars
November 13th 2022With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.
Watch
The Price Paradox of Biosimilar-Like Long-Acting Insulin
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.
Read More
Rheumatologists Grow More Comfortable With Biosimilars, but Concerns Remain
November 4th 2022Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Read More
Dr Timothy Murphy Discusses Successfully Implementing Biosimilars Into Community Cancer Practice
October 28th 2022Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) has had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.
Watch
Dr Paul Forsberg Highlights the Role of the Reference Product Once Biosimilars Hit the Market
October 16th 2022Biosimilars have had such an impact on driving down costs, that in some instances the reference product might be the lowest cost option, explained Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Watch
Considering When to Switch Patients From One Biosimilar to Another
October 9th 2022With more and more biosimilars reaching market, there are considerations around whether to keep patients on their current biosimilar or switch them to another biosimilar as the market dictates, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Watch
Medicare Part B Pricing Changes Aimed at Encouraging Biosimilar Use Begin
October 3rd 2022One of the first parts of the landmark Inflation Reduction Act took effect Monday; it boosts the add-on payment for qualifying biosimilars whose average sales price is not more than the price of its reference product from 6% of the reference product’s ASP to 8% for 5 years.
Read More
Dr Paul Forsberg: Ensuring Consistent, Clear Messaging Critical During Biosimilar Conversion
September 25th 2022When converting a patient to a biosimilar, having clear and consistent messaging will reduce confusion and prevent patients from having a lack of trust in the process, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Watch
Multiple Pegfilgrastim Administration Options Allow for Patient-Centric Model of Care
September 20th 2022With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.
Read More
Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer
September 14th 2022The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy) and metastatic (palliative therapy) breast cancer using real-world data.
Read More
Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan Wilfong
September 11th 2022While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.
Watch
The Biosimilar Conversion Journey Went Through 2 Phases at Minnesota Oncology
September 4th 2022While initially there was a need for education around biosimilars, now there is a need to keep an eye on the evolving biosimilar marketplace and update the formulary of biosimilar medicines, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Watch
Gap After OCM May Cause Some Practices to Switch From Biosimilars to Brand Drugs
September 1st 2022The 1-year gap after the end of the Oncology Care Model (OCM) means some practices have to make hard decisions regarding cost of care or the financial health of the practice, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.
Watch